Healthy Volunteers
Conditions
Keywords
E2511, Healthy Participants
Brief summary
The primary objective of this study is to evaluate the safety, tolerability, and pharmacokinetic (PK) of E2511 following single ascending oral doses in healthy adult and elderly participants.
Interventions
DRUGE2511
E2511 tablets.
DRUGE2511 Matched Placebo
Placebo tablets matching E2511 tablets.
Sponsors
Eisai Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
Yes
Inclusion criteria
1. Non-smoking, age greater than or equal to (\>=) 18 years and less than (\<) 55 years old adult male or female (Cohorts 1 - 6) or age \>=65 years and less than or equal to (\<=) 85 years old elderly male or female (Cohort 7) at the time of informed consent 2. Weight of at least 50 kilogram (kg) and body mass index \>=18 and \<30 kilogram per square meter (kg/m\^2) at Screening
Exclusion criteria
1. Males who have not had a successful vasectomy (confirmed azoospermia) or they and their female partners do not meet the criteria (that is, not of childbearing potential or practicing highly effective contraception throughout the study period plus 90 days after study drug discontinuation). No sperm donation is allowed during the study period plus 90 days after discharge from the study. 2. Females who are breastfeeding or pregnant at Screening or Baseline 3. Females of childbearing potential who: * Within 28 days before study entry, did not use a highly effective method of contraception, * Do not agree to use a highly effective method of contraception (as described above) throughout the entire study period and for 28 days after study drug discontinuation. 4. Clinically significant illness that requires medical treatment within 8 weeks or a clinically significant infection that requires medical treatment within 4 weeks of dosing 5. Evidence of disease that may influence the outcome of the study within 4 weeks before dosing 6. Evidence of disease related to chronic headaches, migraines, joint pain or other disorders or disease resulting in chronic or intermittent pain within 4 weeks before dosing 7. Any personal or family history of seizures (including febrile seizures) or diagnosis of epilepsy or episode of unexplained loss of consciousness 8. Any history of neurological or other medical conditions which in the opinion of the investigator has the potential to reduce seizure threshold 9. Any epileptiform discharges in EEG at Screening 10. A prolonged QT/ QT interval corrected for heart rate (QTc) interval \>450 millisecond \[ms\]) A history of risk factors for torsade de pointes 11. History of prolonged QT/QTc interval 12. Left bundle branch block 13. History of myocardial infarction or active ischemic heart disease 14. History of clinically significant arrhythmia or uncontrolled arrhythmia 15. Any lifetime history of suicidal ideation or any lifetime history of suicidal behavior as indicated by the C-SSRS 16. Any lifetime history of psychiatric disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cohorts 1, 2, 3, 4, 5, 6, 7: Number of Participants With Clinically Significant Change From Screening in Neurological Exam Findings | Cohorts 1, 2, 4, 5, 6, 7: Screening up to Day 1 (approximately 28 days); Cohort 3: Screening up to Day 7 (approximately 35 days) | — |
| Cohorts 1, 2, 3, 4, 5, 6, 7: Number of Participants With Clinically Significant Change From Screening in Psychiatric Assessment | From screening up to 28 days after last dose of study drug (up to 63 days) | Number of participants with clinically significant change in psychiatric assessment will be evaluated by a psychiatrist as a measure of mental health assessment. |
| Cohorts 1, 2, 3, 4, 5, 6, 7: Number of Participants Reporting one or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | From screening up to 28 days after last dose of study drug (up to 63 days) | — |
| Cohorts 1, 2, 3, 4, 5, 6, 7: Number of Participants With Markedly Abnormal Laboratory Values | From screening up to 28 days after last dose of study drug (up to 63 days) | — |
| Cohorts 1, 2, 3, 4, 5, 6, 7: Number of Participants With Clinically Significant Change From Screening in Vital Signs Values | From screening up to 28 days after last dose of study drug (up to 63 days) | — |
| Cohorts 1, 2, 3, 4, 5, 6, 7: Number of Participants With Clinically Significant Change From Screening in Electrocardiograms (ECGs) Findings | From screening up to 28 days after last dose of study drug (up to 63 days) | — |
| Cohorts 1, 2, 3, 4, 5, 6, 7: Number of Participants With Treatment-emergent Suicidal Ideation or Suicidal Behavior as Measured Using Columbia-Suicide Severity Rating Scale (C-SSRS) | From screening up to 28 days after last dose of study drug (up to 63 days) | The C-SSRS (mapped to Columbia Classification Algorithm of Suicide Assessment \[C-CASA\]) is an interview-based rating scale to systematically assess any suicidality, suicidal behavior, or suicidal ideation. Any suicidality is emergence of any suicidal ideation or suicidal behavior. Any suicidal behavior is indicated when response is yes for any these questions- actual attempt to suicide, engaged in non-suicidal self-injurious behavior, interrupted attempt, aborted attempt, preparatory acts. Any suicidal ideation is indicated when response is yes for any of these questions- wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent to suicide. |
| Cohorts 1, 2, 3, 4, 5, 6, 7: Number of Participants With Clinically Significant Change From Screening in Physical Examination Findings | From screening up to 28 days after last dose of study drug (up to 63 days) | — |
| Cohorts 1, 2, 3, 4, 5, 6, 7: Number of Participants With Clinically Significant Change From Screening in Electroencephalogram (EEG) Measurements | From screening up to Day 2 (approximately 30 days) | — |
| Cohorts 1, 2, 3, 4, 5, 6, 7: Maximum Observed Plasma Concentration (Cmax) for E2511 on Day 1 | Day 1: pre-dose up to a potential maximum of 120 hours post-dose | — |
| Cohort 3: Maximum Observed Plasma Concentration (Cmax) for E2511 on Day 7 | Day 7: pre-dose up to a potential maximum of 120 hours post-dose | — |
| Cohorts 1, 2, 3, 4, 5, 6, 7: Time to Reach Cmax (tmax) for E2511 on Day 1 | Day 1: pre-dose up to a potential maximum of 120 hours post-dose | — |
| Cohort 3: Time to Reach Cmax (tmax) for E2511 on Day 7 | Day 7: pre-dose up to a potential maximum of 120 hours post-dose | — |
| Cohorts 1, 2, 3, 4, 5, 6, 7: Area Under the Plasma Concentration-time Curve (AUC(0-t)) From Time Zero to the Last Quantifiable Plasma Concentration for E2511 on Day 1 | Day 1: pre-dose up to a potential maximum of 120 hours post-dose | — |
| Cohort 3: Area Under the Plasma Concentration-time Curve (AUC(0-t)) From Time Zero to the Last Quantifiable Plasma Concentration for E2511 on Day 7 | Day 7: pre-dose up to a potential maximum of 120 hours post-dose | — |
| Cohorts 1, 2, 3, 4, 5, 6, 7: Area Under the Plasma Concentration-time Curve (AUC(0-inf)) From Time Zero to Infinity for E2511 on Day 1 | Day 1: pre-dose up to a potential maximum of 120 hours post-dose | — |
| Cohort 3: Area Under the Plasma Concentration-time Curve (AUC(0-inf)) From Time Zero to Infinity for E2511 on Day 7 | Day 7: pre-dose up to a potential maximum of 120 hours post-dose | — |
| Cohorts 1, 2, 3, 4, 5, 6, 7: Area Under the Plasma Concentration-time Curve (AUC(0-24)) From Time Zero to 24 Hours Postdose for E2511 on Day 1 | Day 1: pre-dose up to a potential maximum of 24 hours post-dose | — |
| Cohort 3: Area Under the Plasma Concentration-time Curve (AUC(0-24)) From Time Zero to 24 Hours Postdose for E2511 on Day 7 | Day 7: pre-dose up to a potential maximum of 24 hours post-dose | — |
| Cohorts 1, 2, 3, 4, 5, 6, 7: Terminal Elimination Phase Half-Life (t1/2) for E2511 on Day 1 | Day 1: pre-dose up to a potential maximum of 120 hours post-dose | — |
| Cohort 3: Terminal Elimination Phase Half-Life (t1/2) for E2511 on Day 7 | Day 7: pre-dose up to a potential maximum of 120 hours post-dose | — |
| Cohorts 1, 2, 3, 4, 5, 6, 7: Apparent Total Clearance (CL/F) for E2511 on Day 1 | Day 1: pre-dose up to a potential maximum of 120 hours post-dose | — |
| Cohort 3: Apparent Total Clearance (CL/F) for E2511 on Day 7 | Day 7: pre-dose up to a potential maximum of 120 hours post-dose | — |
| Cohorts 1, 2, 3, 4, 5, 6, 7: Apparent Volume of Distribution at Terminal Phase (Vz/F) for E2511 on Day 1 | Day 1: pre-dose up to a potential maximum of 120 hours post-dose | — |
| Cohort 3: Apparent Volume of Distribution at Terminal Phase (Vz/F) for E2511 on Day 7 | Day 7: pre-dose up to a potential maximum of 120 hours post-dose | — |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cohort 3: Geometric Mean Ratio of Cmax Between the Fasted and Fed State for E2511 20 mg | Days 1 and 7: pre-dose up to a potential maximum of 120 hours post-dose | — |
| Cohort 3: Geometric Mean Ratio of AUC(0-t) Between the Fasted and fed State for E2511 20 mg | Days 1 and 7: pre-dose up to a potential maximum of 120 hours post-dose | — |
| Cohort 3: Geometric Mean Ratio of AUC(0-inf) Between the Fasted and fed State for E2511 20 mg | Days 1 and 7: pre-dose up to a potential maximum of 120 hours post-dose | — |
| Cohort 3 and Cohort 7: Geometric Mean Ratio of Cmax Between the Healthy Elderly and Adult Participants for E2511 20 mg | Cohort 3: Days 1 and 7: pre-dose up to a potential maximum of 120 hours post-dose; Cohort 7: Day 1: pre-dose up to a potential maximum of 120 hours post-dose | — |
| Cohort 3 and Cohort 7: Geometric Mean Ratio of AUC(0-t) Between the Healthy Elderly and Adult Participants for E2511 20 mg | Cohort 3: Days 1 and 7: pre-dose up to a potential maximum of 120 hours post-dose; Cohort 7: Day 1: pre-dose up to a potential maximum of 120 hours post-dose | — |
| Cohort 3 and Cohort 7: Geometric Mean Ratio of AUC(0-inf) Between the Healthy Elderly and Adult Participants for E2511 20 mg | Cohort 3: Days 1 and 7: pre-dose up to a potential maximum of 120 hours post-dose; Cohort 7: Day 1: pre-dose up to a potential maximum of 120 hours post-dose | — |
| Cohorts 1, 2, 3, 4, 5, 6, 7: Correlation Between QTc and E2511 Plasma Concentrations | Day 1: Pre-dose through 24 hours post dose | To explore the correlation between changes in QTc interval (msec) and E2511 plasma concentrations, appropriate correction method for QTc interval calculation such as QTcF will used for analysis. Holter monitors will be used to collect continuous 12-lead ECG data, from which high precision ECG recordings will be extracted from the Holter monitor data prior to the PK blood samples collected. |
Countries
United States
Outcome results
None listed